International multicenter randomized phase III study of first-line erlotinib (E) followed by second-line cisplatin plus gemcitabine (CG) versus first-line CG followed by second-line E in advanced non-small cell lung cancer (aNSCLC): The TORCH trial.
2010 ◽
Vol 28
(15_suppl)
◽
pp. 7508-7508
◽
Keyword(s):
Keyword(s):
2005 ◽
Vol 23
(33)
◽
pp. 8389-8395
◽
Keyword(s):
Keyword(s):
2015 ◽
Vol 10
(1)
◽
pp. 134-142
◽
Keyword(s):
Keyword(s):
Keyword(s):
2014 ◽
Vol 32
(15_suppl)
◽
pp. 8056-8056
◽
Keyword(s):
2014 ◽
Vol 32
(15_suppl)
◽
pp. 8046-8046
◽
Keyword(s):
Keyword(s):
2015 ◽
Vol 45
(7)
◽
pp. 670-676
◽
Keyword(s):